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INTRODUCTION
Respiratory distress syndrome (RDS) is one of the
main causes of infant death during the newborn
period.1-3 The incidence of respiratory distress syn-
drome (RDS) has been associated with maternal
gestational age and birth weight of the newborn,
which characterized by difficulty of breathing in in-
fants, signed by the presence the two of four im-
portant symptoms: tachypneu (> 60 bpm), cyano-
sis, retraction of the ribs and sternum, and expira-
tory groaning.4-6
In an effort to reduce the incidence and the se-
verity of RDS during threatening preterm delivery,
the mother is administered with antenatal steroids
or the prophylactic surfactant which can be given
when resuscitate the newborn, or both. There have
Abstract
Objective: To compare the effectivity of N-acetylcysteine with Be-
tamethasone in fetal lung maturation.
Methods: This research was a double blind randomized clinical tri-
als in women threatened by preterm delivery (28 to 34 weeks of
gestation).
Results: There were 90 subjects randomly assigned to N-acetylcys-
teine group (n=30), betamethasone group (n=30), and the control
group (who had not been given a tocolytic, n=30). Fetal lung matu-
ration was assessed with the p. The values for lung maturation at
random were 5 foams. After being tested with the Tapp, there were
significant differences between the 3 groups of this study based on
analysis of variance (ANOVA) (p = 0.001). The average foam on the
N-acetylcysteine was 4.8 ± 1.3 while in the group Betamethasone,
was 3.2 ± 1.0, and the average amount of foam in the control group
was 5.5 ± 1.6. The end point of the Tapp were mature and immature,
which in the N-acetylcysteine group there were 21 subjects (70.0%)
with mature lung, Betamethasone groups 28 subjects (93.3%) with
mature lungs, whereas in the control group, there were 15 subjects
(50.0%) with mature lung.
Conclusion: Betamethasone was more effective than N-acetylcyste-
ine for lung maturation in women threatened with preterm delivery.
[Indones J Obstet Gynecol 2013; 37-1: 21-5]
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Abstrak
Tujuan: Membandingkan efektivitas pemberian N-acetylcystein de-
ngan Betametason untuk pematangan paru janin.
Metode: Penelitian ini merupakan penelitian uji klinis acak buta
ganda pada wanita dengan ancaman persalinan preterm (usia 28
sampai 34 minggu).
Hasil: Terdapat 90 subjek penelitian yang dipilih secara acak seder-
hana, pada kelompok N-acetylcystein (n=30), kelompok betametason
(n=30), dan kelompok kontrol (yang tidak sempat diberi tokolitik,
n=30). Penilaian kematangan paru janin dilakukan dengan uji Tapp.
Batas nilai untuk maturasi paru secara acak adalah 5 busa. Setelah
dilakukan uji Tapp, didapatkan perbedaan yang bermakna dari 3
kelompok penelitian ini berdasarkan analisis varian (Anova)
(p=0,001), didapatkan rerata busa pada kelompok N-acetylcystein se-
besar 4,8±1,3 sedangkan pada kelompok Betametason lebih sedikit
dibandingkan kelompok N-acetylcystein yaitu 3,2±1,0, sementara re-
rata jumlah busa pada kelompok kontrol sebanyak 5,5±1,6. Hasil akhir
uji Tapp adalah matur dan imatur, pada kelompok N-acetylcystein di-
dapatkan 21 subjek (70,0%) dengan paru matur, kelompok Betame-
tason sebanyak 28 subjek (93,3%) dengan paru matur serta meru-
pakan kelompok yang paling banyak mengalami paru matur, sedang-
kan pada kelompok kontrol, didapatkan 15 subjek (50,0%) dengan
paru matur.
Kesimpulan: Betametason lebih efektif dibandingkan N-acetylcystein
sebagai pematangan paru pada wanita dengan ancaman persalinan
preterm.
[Maj Obstet Ginekol Indones 2013: 37-1: 21-5]
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been many studies conducted on the use of ante-
natal steroids with result in reducing of RDS by
50% as demonstrated by Liggins and Howie
(1972) and by the NIH Consensus Development
Panel (1994) with the conclusion that there is of
no evidence of side effects of corticosteroid use in
pregnancies with hypertension, gestational diabe-
tes, multiple pregnancy, intrauterine growth res-
triction and fetal hydrops.7-10
The use of N-acetylcysteine to increase the levels
of surfactant, was first conducted in 1980, in pa-
tients underwent lung surgery. They evaluated the
surface tension of the specimen from lung biopsy.
Based on this study, it is known that administration
of i.m. 2 x 300 mg NAC significantly increased the
activity of the superficial alveolar epithelial fluid by
lowering the surface tension and increased the
elasticity of lung tissues.11 Administration of N-ace-
tylcysteine in pregnant women who experienced
acetaminophen intoxication, can be measured in
umbilical blood, proving that N-acetylcysteine had
the ability to pass through the placental barrier. N-
acetylcysteine was also safe in pregnant and lactat-
ing women.12
METHODS
This research was a randomized double blind clini-
cal trials in pregnant women threatened with pre-
term delivery (28 to 34 weeks) in RSMH Palem-
bang. The study started in August 2010 and ended
in February 2012. Inclusion criteria included wo-
men with 28-34 weeks of pregnancy threatened by
preterm delivery, proven by an ultrasound exami-
nation and gave birth before 35 weeks of gestation,
willing to join the study and signed the informed
consent, and had never received medication for
lung maturation in the past pregnancy. Patients
who met the study criteria were then checked for
physical examination, complete blood count, urina-
lysis and ultrasound examination. Then the data
was recorded in the record of research and study
registry book. Patients who were already in a state
of labor were assigned to group 3 (control group)
and been followed until the delivery. Patients who
were given tocolytics, performed simply randomly
with the aid of random table made by residents
who had been trained previously to determine the
group 1 (N-Acetylcysteine) and group 2 (Betame-
thasone). If side effects occur, the patient dropped
out and treated according to the symptoms. The
newborn birth weight, Apgar scores and the onset
of RDS were observed during the treatment, indi-
cated by clinical symptoms of dyspnoea (60x/min),
cyanosis, grunting, and retractions, and then the
severity of asphyxia was determined by Apgar
scores (mild, moderate and severe asphyxia). The
neonates will then underwent chest radiology ex-
amination. Patients received the tocolytic protocol,
including Nifedipine 10mg per oral, which can be
repeated 2-3 times/day, and continued every 8
hours until the contraction disappeared. Mothers
who gave birth before 35 weeks of gestation, were
tested with lung maturation test. One cc of Am-
niotic fluid sample was taken if the membrane rup-
tured >24 hours after the last drug administration.
Assessment of fetal lung maturation performed
with the Tapp test.
Data were collected in the form of research that
has been prepared. Statistical processing of data
was performed using SPSS 14 program, using Chi
Square test, T-test and Anova test.
RESULTS
Of the 90 subjects, the group that received N-ace-
tylcysteine 300 mg i.m. for 3 days (n = 30), be-
tamethasone group 12 mg qd i.v. for 2 days (n =
30) and the control group (who had not given a
tocolytic, n = 30), the age distribution of subjects
are mostly in the age group of 20-35 years, with a
body mass index of 18.5 to 25, housewife, gradu-
ated from high school, and the pregnancy was in
the 33-34 weeks of gestation. According to the sta-
tistical analysis performed, which was chi-square
and ANOVA, there was no significant difference in
general characteristics of the three groups.
Assessment of fetal lung maturity was per-
formed with the Tapp test. After testing the Tapp,
the average number of foam in the group receiving
N-acetylcysteine was 4.8 ± 1.3 and there was sig-
nificant difference in the amount of foam before
and after the Tapp test on the N-acetylcysteine
group (p = 0.001). On Betamethasone group the
average number of foam was less than the N-ace-
tylcysteine group, which was 3.2 ± 1.0, even though
there was also a significant difference in the num-
ber of foam before and after the Tapp test on Be-
tamethasone group (p = 0.001). Meanwhile, the av-
erage number of foam in the control group after
the test was as much as 5.5 ± 1.6, but there was
no significant difference in the number of foam be-
fore and after the Tapp test in the control group
(p = 0.077). The mean amount of foam of each re-
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search group based on a complete test of the Tapp
can be seen in Table 2.
Table 2. The average of foam in each group after
the Tapp test
Group
Foam
p
Before After
N-acetylcysteine 6.0±0.0 4.8±1.3 0.001
Betamethasone 6.0±0.0 3.2±1.0 0.001
Control 6.0±0.0 5.5±1.6 0.077
T-Pairs test
Then analysis of variance (ANOVA) was being
performed to see the overall differences in the
three study groups, statistical test results found a
significant differences (p = 0.001) in the amount of
foam in all three study groups. Analysis of variance
(ANOVA) of the three groups was based on the
Tapp test (Table 3).
Table 3. Variance analysis on the three groups based
the Tapp test
Foam
Groups
p*
N-acetyl
cysteine
Betametha
sone
Control
Before 6.0±0.0 6.0±0.0 6.0±0.0 0.999
After 4.8±1.3 3.2±1.0 5.5±1.6 0.001
* ANOVA test
The end result of the Tapp test was categorized
into mature and immature. We found that there
were 21 subjects (70.0%) in the N-acetylcysteine
groups with mature lung and 28 subjects (93.3%)
in the bethametasone group. Whereas in the con-
trol group, there were 15 subjects (50.0%) with
mature lung, as listed in Table 4. Thus, it can be
said that the administration of Betamethasone was
more effective for lung maturation in women
threatened with preterm delivery compared with
N-Acetylcystein.
Table 1. General Characteristic of the subjects
Characteristic N-acetylcysteine N %
Betamethasone
N %
Control
N % p
Age (years)
< 20
20-35
> 35
 2 (6.7) 
24 (80.0)
 4 (13.3)
 0 (0.0) 
25 (83.3)
 5 (16.7)
 3 (10.0)
23 (76.7)
 4 (13.3)
0.552
BMI
18.5-25
> 25
18 (60) 
12 (40) 
18 (60.0)
12 (40.0)
20 (66.7)
10 (33.3)
0.828
Occupation
Housewife
Laborer
Civil Servant
22 (73.3)
 3 (10.0)
 5 (16.7)
22 (73.3)
 4 (13.3)
 4 (13.3)
27 (90.0)
 1 (3.3) 
 2 (6.7) 
0.444
Education
Junior high school
Senior high school
Bachelor
 8 (26.7)
20 (66.7)
 2 (6.7) 
 9 (30.0)
18 (60.0)
 3 (10.0)
 6 (20.0)
22 (73.3)
 2 (6.7) 
0.862
Parity
1
2
3
4
18 (60.0)
 5 (16.7)
 5 (16.7)
 2 (6.7) 
14 (46.7)
10 (33.3)
 5 (16.7)
 1 (3.3) 
18 (60.0)
 9 (30.0)
 3 (10.0)
 0 (0.0) 
0.543
Gestation
33-34 (w)
< 33 (w)
20 (66.7)
10 (33.3)
22 (73.3)
 8 (26.7)
14 (46.7)
16 (53.3)
0.086
Chi- Square test
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Table 4. Lung Maturation After Administration of N-
 Acetylcysteine Compared with Betamethasone
 in women threaten preterm delivery
Group
Test Tapp
N(=90)
Mature (%) Immature (%)
N-acetylcysteine 21 (70.0) 9 (30.0) 30 (100.0)
Betamethasone 28 (93.3) 2 (7.7) 30 (100.0)
Control 15 (50.0) 15 (50.0) 30 (100.0)
DISCUSSIONS
Of the three groups there were no significant dif-
ferences in general characteristic included age dis-
tribution of the subject which is mostly in the age
group 20-35 years, with a body mass index of 18.5
to 25, housewife, graduated from high school, and
had pregnancy of 33-34 weeks gestation, with p>
0.05. So that, it can be concluded that the subjects
in this study was homogen and the final conclu-
sions about the effectiveness of therapy among the
three groups can be made.
Assessment of fetal lung maturation performed
with the Tapp tests. Limit values for lung matura-
tion at random was 5 foams. If there were no more
than 5 foams on the ether layer, the lung is con-
sidered as a mature lung.13-16 After performed the
Tapp test, there was a significant differences from
the 3 groups of this study which was based on
analysis of variance (ANOVA) (p = 0.001), the av-
erage foam on the N-acetylcysteine was 4.8 ± 1.3,
while in the group Betamethasone it was 3.2 ± 1.0,
and in the control group was 5.5 ± 1.6. The end
result of the Tapp test was categorized into mature
and immature. There were 21 subjects (70.0%) in
the N-acetylcysteine groups with mature lung and
28 subjects (93.3%) in the betamethasone group.
Whereas in the control group, there were 15 sub-
jects (50.0%) with mature lung. Based on the re-
sults of research Utami (2009) suggested the ad-
ministration of a combination of N-acetylcysteine
and Dexamethasone (77.3%) was proven to be
more effective in lung maturation compared to the
administration of only N-acetylcysteine (54.5%) or
dexamethasone (36.4%).17 In the meantime, Ra-
hardjo study (2003) demonstrated that the 85.7%
of patients receiving a combination of N-acetylcys-
teine and Dexamethasone achieved lung matura-
tion, while only 57.2% of patients receiving a single
dexamethasone administration achieved the same
result.18 The study on the role of N-acetylcysteine
on lung was first described in the study by Mereto
(1980) of 16 patients underwent thoracotomy sur-
gery and also by Muller (2001), reporting the abil-
ity of NAC to protect against damage of surfactant
metabolism by NO2.11,19-21 Mechanism of action of
NAC itself in the process of fetal lung maturation
was as a precursor of glutathione, to prevent lipid
peroxydation and inactivation of surfactant due to
reactive oxygen compounds on the pneumosit type
II.22-26 This study showed that the use of corticos-
teroids, in this case betamethasone, more effective
than the use of NAC in fetal lung maturation in
women threatened with preterm delivery.
CONCLUSIONS
The effectivity of N-acetylcysteine for fetal lung
maturation in women threatened with preterm de-
livery was 70.0%, meanwhile Betamethasone, it
was 93.3%. It can be concluded that Betametha-
sone was more effective than N-acetylcysteine for
lung maturation in women threatened with pre-
term delivery.
SUGGESTIONS
Betamethasone administration is recommended
for fetal lung maturation in women threatened
with preterm delivery. Further research is needed
with a larger number of samples in order to obtain
data that can support the role of N-acetylcysteine
drug in lung maturation.
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